Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $37.4900 (-3.92%) ($37.4900 - $37.4900) on Wed. Jul. 7, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.83% (three month average) | RSI | 56 | Latest Price | $37.4900(-3.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) IWO(59%) ARKK(58%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.415% in a week (0% probabilities). VIXM(-46%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.415% (StdDev 2.83%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $38.3 | 5 Day Moving Average | $39.19(-4.34%) | 10 Day Moving Average | $38.95(-3.75%) | 20 Day Moving Average | $38.3(-2.11%) | To recent high | -19.3% | To recent low | 15.6% | Market Cap | $4.748b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |